Benign prostatic hyperplasia and prostate cancer differentiation via platelet to lymphocyte ratio

Cancer Biomarkers

Volumn 15, Issue 3, 2015, Pages 317-323

  Kaynar, Mehmet ^a   Yildirim, Mehmet Erol ^b   Gul, Murat ^a   Kilic, Ozcan ^a   Ceylan, Kadir ^a   Goktas, Serdar ^a  

^a SELCUK UNIVERSITY FACULTY OF MEDICINE   (Turkey)

^b TURGUT OZAL UNIVERSITY   (Turkey)

Author keywords

Benign prostatic hyperplasia; platelet to lymphocyte ratio; prostate cancer

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ARTICLE; CHRONIC PROSTATITIS; GLEASON SCORE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PATHOLOGY; PLATELET LYMPHOCYTE RATIO; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATE VOLUME; RETROSPECTIVE STUDY; ADENOCARCINOMA; AGED; BLOOD; DIFFERENTIAL DIAGNOSIS; LYMPHOCYTE; MIDDLE AGED; NEUTROPHIL; PHYSIOLOGY; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; THROMBOCYTE; VERY ELDERLY;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; BLOOD PLATELETS; DIAGNOSIS, DIFFERENTIAL; HUMANS; INFLAMMATION; LYMPHOCYTES; MALE; MIDDLE AGED; NEUTROPHILS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 84931045121     PISSN: 15740153     EISSN: 18758592     Source Type: Journal    
DOI: 10.3233/CBM-150458     Document Type: Article

References (38)

1. A. Jemal, R.C. Tiwari, T Murray, A. Ghafoor. Cancer statistics, CA Cancer J. Clin 54 (2004), 8-29.
2. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med 349 (2003), 366-81.
3. Garzotto M, Hudson RG, Peters L, Hsieh YC, Barrera E, Mori M, Beer TM, Klein T. Predictive modelling the presence of prostate carcinoma using clinical, laboratory, and ultrasound parameters in patients with prostate specific antigen levels ≤ 10 ng/mL. Cancer 98 (2003), 1417, 22.
4. Okada K, Kojima M, Naya Y, Kamoi K, Yokoyama K, Takamatsu T, Miki T. Correlation of histological inflammation in needle biopsy specimens with serum prostate-specific antigen levels in men with negative biopsy for prostate cancer. Urology 55 (2000), 892-8.
5. Bardan R, Dumache R, Dema A, Cumpanas A, Bucuras V. The role of prostatic inflammation biomarkers in the diagnosis of prostate diseases. Clin Biochem (2014), 20. pii: S0009-9120(14) 00069-1.
6. Menschikowski M, Hagelgans A, Fuessel S, Mareninova OA, Neumeister V, Wirth MP, Siegert G. Serum levels of secreted group IIA phospholipase A(2) in benign prostatic hyperplasia and prostate cancer: a biomarker for inflammation or neoplasia? Inflammation 35 (2012), 1113-8.
7. Klinger MH, Jelkmann W. Role of blood platelets in infection and inflammation. J Interferon Cytokine Res 22 (2002), 913-22.
8. Alexandrakis MG, Passam FH, Moschandrea IA, Christophoridou AV, Pappa CA, Coulocheri SA, Kyriakou DS. Levels of serum cytokines and acute phase proteins in patients with essential and cancer-related thrombocytosis. Am J ClinOncol 26 (2003), 135-40.
9. Potter SR, Horniger W, Tinzl M, Bartsch G, Partin A. Age, prostate specific antigen and digital rectal examination as determinants of the probability of having prostate cancer. Urology 57 (2001), 1100-1104.
10. McDonald AC, Vira MA, Vidal AC, Gan W, Freedland SJ, Taioli E. Association between systemic inflammatory markers and serum prostate-specific antigen in men without prostatic disease - the 2001-2008 National Health and Nutrition Examination Survey Prostate 74 (2014), 561-7.
11. Smith RA, Bosonnet L, Ghaneh P, Sutton R, Evans J, Healey P, Garvey C, Hughes M, Raraty M, Campbell F, Neoptolemos JP. The platelet-lymphocyte ratio improves the predictive value of serum CA19-9 levels in determining patient selection for staging laparoscopy in suspected periampullary cancer. Surgery 143 (2008), 658-66.
12. Acmaz G, Aksoy H, Unal D, Ozyurt S, Cingillioglu B, Aksoy U, Muderris I. Are neutrophil/lymphocyte and platelet/ lymphocyte ratios associated with endometrial precancerous and cancerous lesions in patients with abnormal uterine bleeding? Asian Pac J Cancer Prev 15 (2014), 1689-92.
13. Schenk JM, Kristal AR, Arnold KB, Tangen CM, Neuhouser ML, Lin DW, White E, Thompson IM. Association of symptomatic benign prostatic hyperplasia and prostate cancer: results from the prostate cancer prevention trial. Am J Epidemiol 173 (2011), 1419-28.
14. Drake CG. Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol 10 (2010), 580-93.
15. Sciarra A, Di Silverio F, Salciccia S, Autran Gomez AM, Gentilucci A, Gentile V. Inflammation and chronic prostatic diseases: evidence for a link? Eur Urol 52 (2007), 964-72.
16. Sfanos KS, De Marzo AM Prostate cancer and inflammation: the evidence. Histopathology 6 (2012), 199-215.
17. Nickel JC, Roehrborn CG, O'Leary MP, Bostwick DG, Somerville MC, Rittmaster RS. The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol 54 (2008), 1379-84.
18. Di Silverio F, Gentile V, De Matteis A, Mariotti G, Giuseppe V, Luigi PA, Sciarra A. Distribution of inflammation, premalignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. EurUrol 43 (2003), 164-75.
19. Steiner G, Gessl A, Kramer G, Schöllhammer A, Förster O, Marberger M. Phenotype and function of peripheral and prostatic lymphocytes in patients with benign prostatic hyperplasia. J Urol 151 (1994), 480-4.
20. Nickel JC. Inflammation and benign prostatic hyperplasia. UrolClin North Am 35 (2008), 109-15.
21. Buergy D, Wenz F, Groden C, Brockmann MA. Tumor-platelet interaction in solid tumors. Int J Cancer 130 (2012), 2747-60.
22. Klinger MH, Jelkmann W. Role of blood platelets in infection and inflammation. J Interferon Cytokine Res 22 (2002), 913-22.
23. Omabe M, Ezeani M. Infection, inflammation and prostate carcinogenesis. Infect Genet Evol 11 (2011), 1195-8.
24. Wang DS, Ren C, Qiu MZ, Luo HY, Wang ZQ, Zhang DS, et al. Comparison of the prognostic value of various preoperative inflammation-based factors in patients with stage III gastric cancer. Tumour Biol 33 (2012), 749-56.
25. Kemal Y, Yucel I, Ekiz K, Demirag G, Yilmaz B, Teker F, Ozdemir M. Elevated serum neutrophil to lymphocyte and platelet to lymphocyte ratios could be useful in lung cancer diagnosis. Asian Pac J Cancer Prev 15 (2014), 2651-4.
26. Blay JY, Negrier S, Combaret V, Attali S, Goillot E, Merrouche Y, Mercatello A, Ravault A, Tourani JM, Moskovtchenko JF, et al. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res 52 (1992), 3317-22.
27. Nakashima J, Tachibana M, Horiguchi Y, Oya M, Ohigashi T, Asakura H, Murai M. Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res 6 (2000), 2702-6.
28. Smith R, Bosonnet L, Raraty M, et al. Preoperative platelet- lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma. Am J Surg 197 (2009), 466-72.
29. Kwon HC, Kim SH, Oh SY, Lee S, Lee JH, Choi HJ, Park KJ, Roh MS, Kim SG, Kim HJ, Lee JH. Clinical significance of preoperative neutrophil-lymphocyte versus platelet-lymphocyte ratio in patients with operable colorectal cancer. Biomarkers 17 (2012), 216-22.
30. Asher V, Lee J, Innamaa A, Bali A. Preoperative platelet lymphocyte ratio as an independent prognostic marker in ovarian cancer. Clin Transl Oncol 13 (2011), 499-503.
31. Raungkaewmanee S, Tangjitgamol S, Manusirivithaya S, Srijaipracharoen S, Thavaramara T Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer. J Gynecol Oncol 23 (2012), 265-73.
32. Robert G, Descazeaud A, Nicolaïew N, Terry S, Sirab N, Vacherot F, Maillé P, Allory Y, de la Taille A. Inflammation in benign prostatic hyperplasia: a 282 patients' immunohistochemical analysis. Prostate 69 (2009), 1774-80.
33. Caruso C, Balistreri CR, Candore G, Carruba G, ColonnaRomano G, Di Bona D, Forte GI, Lio D, Listì F, Scola L, Vasto S. Polymorphisms of proinflammatory genes and prostate cancer risk: a pharmacogenomic approach. Cancer Immunol Immunother 58 (2009), 1919-33.
34. Djavan B, Eckersberger E, Espinosa G, et al. Complex mechanisms in prostatic inflammatory response. Eur Urol Suppl 8 (2009), 872-8.
35. Ponniah S, Arah I, Alexander RB. PSA is a candidate self-antigen in autoimmune chronic prostatitis/chronic pelvic pain syndrome. Prostate 44 (2000), 49-54.
36. McDonald AC, Vira MA, Vidal AC, Gan W, Freedland SJ, Taioli E. Association between systemic inflammatory markers and serum prostate-specific antigen in men without prostatic disease - the 2001-2008 National Health and Nutrition Examination Survey Prostate 74 (2014), 561-567.
37. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 350 (2004), 2239-4.
38. Irani J, Levillain P, Goujon JM, Bon D, Doré B, Aubert J. Inflammation in benign prostatic hyperplasia: correlation with prostate specific antigen. value J Urol 157 (1997), 1301-3.